![Peter Goodfellow](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Peter Goodfellow
Président chez
Gammadelta Therapeutics Ltd.
Profil
Peter Goodfellow is currently the Chairman at Gammadelta Therapeutics Ltd., Adaptate Biotherapeutics Ltd., and Senior Advisor at Abingworth LLP.
Previously, he held positions as Director at deCODE genetics, Inc., Director at The Institute of Cancer Research: Royal Cancer Hospital, Director-Supervisory Board at Prosensa Holding NV, Director at Muscular Dystrophy Campaign Ltd., and Director at Virion Biotherapeutics Ltd. He also served as Senior Vice President-Discovery Research at GSK Plc and as a Professor at the University of Cambridge.
Dr. Goodfellow obtained a doctorate degree from the University of Oxford and completed undergraduate and doctorate degrees at the University of Bristol.
Postes actifs de Peter Goodfellow
| Sociétés | Poste | Début |
|---|---|---|
Gammadelta Therapeutics Ltd.
 Gammadelta Therapeutics Ltd. BiotechnologyHealth Technology Operates biotechnology company that engages in discovery and development of allogeneic gamma delta T cell therapies for cancer | Président | - |
Adaptate Biotherapeutics Ltd.
 Adaptate Biotherapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in research and experimental development on biotechnology | Président | - |
Abingworth LLP
 Abingworth LLP Investment ManagersFinance Abingworth invests in both private and public companies located across Europe and the United States. The firm targets companies operating in the fields of life sciences and healthcare sectors. It provide financing for seed, early, later and clinical co-development stage capital requirements with an investment size of USD 15 - 30 million. | Consultant / Advisor | - |
Anciens postes connus de Peter Goodfellow
| Sociétés | Poste | Fin |
|---|---|---|
| GENSIGHT BIOLOGICS S.A. | Directeur/Membre du Conseil | 21/06/2023 |
deCODE genetics, Inc.
 deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology Is a bio-pharmaceutical company | Directeur/Membre du Conseil | 13/07/2010 |
| GSK PLC | Directeur Technique/Scientifique/R&D | - |
University of Cambridge
 University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Virion Biotherapeutics Ltd.
 Virion Biotherapeutics Ltd. BiotechnologyHealth Technology Engages in research in biotechnology for developing therapies for respiratory viral infections | Directeur/Membre du Conseil | - |
Formation de Peter Goodfellow
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
75
Relations au 1er degré
13
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 13 |
|---|---|
deCODE genetics, Inc.
deCODE genetics, Inc. Pharmaceuticals: GenericHealth Technology Is a bio-pharmaceutical company | Health Technology |
The Institute of Cancer Research: Royal Cancer Hospital
 The Institute of Cancer Research: Royal Cancer Hospital Miscellaneous Commercial ServicesCommercial Services Operates as a cancer research institution | Commercial Services |
GSK Plc
 GSK Plc Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes vaccines and other pharmaceutical products | Health Technology |
Abingworth LLP
Abingworth LLP Investment ManagersFinance Abingworth invests in both private and public companies located across Europe and the United States. The firm targets companies operating in the fields of life sciences and healthcare sectors. It provide financing for seed, early, later and clinical co-development stage capital requirements with an investment size of USD 15 - 30 million. | Finance |
University of Oxford
 University of Oxford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Cambridge
University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Bristol
 University of Bristol Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Prosensa Holding NV
 Prosensa Holding NV BiotechnologyHealth Technology Engages in the development of ribonucleic acid-modulating or RNA-modulating, therapeutics for the treatment of genetic disorders | Health Technology |
Muscular Dystrophy Campaign Ltd. | |
Gensight Biologics SA
 Gensight Biologics SA Pharmaceuticals: MajorHealth Technology Manufactures and markets novel therapies for severe retinal neurodegenerative diseases | Health Technology |
Gammadelta Therapeutics Ltd.
Gammadelta Therapeutics Ltd. BiotechnologyHealth Technology Operates biotechnology company that engages in discovery and development of allogeneic gamma delta T cell therapies for cancer | Health Technology |
Virion Biotherapeutics Ltd.
Virion Biotherapeutics Ltd. BiotechnologyHealth Technology Engages in research in biotechnology for developing therapies for respiratory viral infections | Health Technology |
Adaptate Biotherapeutics Ltd.
Adaptate Biotherapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in research and experimental development on biotechnology | Commercial Services |
